EBV-Driven CD4+ T Cells Link Epstein-Barr Virus to MS, Opening Immunotherapy Avenues
New research shows Epstein–Barr virus activates CD4+ T cells that attack nerve insulation in multiple sclerosis, and that anti-CD20 therapies (which reduce B cells and viral stimuli) lower CD4+ T-cell responses and EBV activity—hinting immunotherapies could slow relapses and progression.